Cantel Medical Corp. (CMD) Receives Average Recommendation of “Hold” from Analysts
Cantel Medical Corp. (NYSE:CMD) has been assigned an average broker rating score of 2.50 (Hold) from the four analysts that provide coverage for the company, Zacks Investment Research reports. Three research analysts have rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. Cantel Medical’s rating score has declined by 25% from three months ago as a result of various analysts’ upgrades and downgrades.
Zacks has also given Cantel Medical an industry rank of 106 out of 265 based on the ratings given to related companies.
Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Cantel Medical in a research note on Friday, September 1st.
Cantel Medical (NYSE:CMD) last announced its quarterly earnings results on Thursday, September 28th. The company reported $0.54 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.52 by $0.02. Cantel Medical had a net margin of 9.50% and a return on equity of 17.42%. The firm had revenue of $205.50 million for the quarter, compared to analyst estimates of $200.32 million. The company’s revenue was up 14.8% on a year-over-year basis. research analysts forecast that Cantel Medical will post 2.35 EPS for the current year.
The business also recently declared a Semi-Annual dividend, which will be paid on Wednesday, January 31st. Shareholders of record on Wednesday, January 17th will be paid a $0.085 dividend. The ex-dividend date is Tuesday, January 16th. This represents a yield of 0.17%. This is a positive change from Cantel Medical’s previous Semi-Annual dividend of $0.07. Cantel Medical’s payout ratio is presently 7.73%.
In other news, EVP Eric W. Nodiff sold 2,868 shares of the business’s stock in a transaction on Friday, October 20th. The shares were sold at an average price of $97.55, for a total value of $279,773.40. Following the sale, the executive vice president now owns 39,102 shares of the company’s stock, valued at $3,814,400.10. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director George L. Fotiades sold 6,000 shares of the business’s stock in a transaction on Friday, October 13th. The stock was sold at an average price of $95.23, for a total transaction of $571,380.00. The disclosure for this sale can be found here. In the last three months, insiders sold 36,368 shares of company stock worth $3,576,028. 12.30% of the stock is currently owned by insiders.
Hedge funds have recently made changes to their positions in the company. Globeflex Capital L P bought a new stake in shares of Cantel Medical in the second quarter worth $114,000. Airain ltd bought a new stake in shares of Cantel Medical in the second quarter worth $201,000. Punch & Associates Investment Management Inc. bought a new stake in shares of Cantel Medical in the second quarter worth $212,000. Hartford Investment Management Co. bought a new stake in shares of Cantel Medical in the third quarter worth $217,000. Finally, Riverhead Capital Management LLC bought a new stake in shares of Cantel Medical in the second quarter worth $218,000. 84.67% of the stock is currently owned by institutional investors and hedge funds.
About Cantel Medical
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with MarketBeat.com's FREE daily email newsletter.